Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

A pivotal study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...

Genentech, part of the Roche (ROG SIX) group, has received a new approval from the US Food and Drug Administration for TNKase ...

Older adults who are admitted to the hospital with their first ischemic stroke who have poor nutritional status upon admission have a higher risk of post-stroke myocardial injury, a study shows.

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

FDA approval was based on the AcT noninferiority trial that found tenecteplase (at 0.25 mg/kg) to be at least on par with alteplase for safety and efficacy in acute ischemic stroke in Canadians ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

A molecule called glial fibrillary acidic protein (GFAP) rose significantly in the blood of patients who underwent ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...